Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Spinal and Bulbar Muscular Atrophy Clinical Trial

Official title:
A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Status Completed

Clinical Trial Summary

The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Atrophy
Bulbo-Spinal Atrophy, X-Linked
Muscular Atrophy
Spinal and Bulbar Muscular Atrophy

Clinical Trial Details

NCT number	NCT02024932
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	February 4, 2014
Completion date	April 13, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04944940` - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting	`NCT03555578` - Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Completed	`NCT00303446` - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	Phase 2
Recruiting	`NCT06411912` - A Study of NIDO-361 in Patients With SBMA	Phase 2
Completed	`NCT02156141` - High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy	N/A
Active, not recruiting	`NCT05517603` - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients	Phase 1/Phase 2
Recruiting	`NCT06169046` - A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy	Phase 2